<p>Cypress Capital Group 在第二季度减持了 Hologic, Inc.（NASDAQ:HOLX - Free Report）的持股，根据该公司最近向证券交易委员会（SEC）提交的文件，持股比例下降了 75.9%。该公司在此期间卖出了 9,607 股，持有这家医疗设备提供商的 3,050 股股票。截至最近一次提交的 SEC 文件，Cypress Capital Group 持有的 Hologic 股份价值 226,000 美元。</p>
<ul>
<li>是时候购买这 3 家提高收入预测的医疗公司了吗？</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也买入和卖出了该公司的股票。iA Global Asset Management Inc.在第一季度新建了 Hologic 的头寸，价值约 37,000 美元。Mather Group LLC.在第一季度购入了一份价值约 48,000 美元的 Hologic 股票。Massmutual Trust Co. FSB ADV 在第一季度将其在 Hologic 的持仓增加了 24.7%。Massmutual Trust Co. FSB ADV 现在拥有 691 股这家医疗设备提供商的股票，价值 54,000 美元，比上一季度增加了 137 股。Toth Financial Advisory Corp 在第一季度将其在 Hologic 的持股增加了 81.1%。Toth Financial Advisory Corp 现在拥有 775 股这家医疗设备提供商的股票，价值 60,000 美元，比上一季度增加了 347 股。最后，Fidelis Capital Partners LLC 在第一季度购入了一份价值约 63,000 美元的 Hologic 股票。94.73% 的股份由对冲基金和其他机构投资者持有。</p>
<h2>Hologic 股价表现</h2>
<p>NASDAQ HOLX 股票在周五的午间交易中上涨了 0.16 美元，达到 80.25 美元。公司股票交易量为 1,106,135 股，相比其平均交易量 1,648,404 股有所下降。Hologic, Inc.的 52 周最低价为 64.02 美元，52 周最高价为 84.67 美元。该公司的市值为 187.3 亿美元，市盈率为 40.94，市盈增长比为 2.64，贝塔系数为 0.99。股票的 50 天简单移动平均线为 77.75 美元，200 天简单移动平均线为 76.14 美元。公司的资产负债比为 0.51，流动比率为 3.99，速动比率为 3.29。</p>
<ul>
<li>蝴蝶网络能否在 2023 年扩展业务？</li>
</ul>
<p>Hologic（NASDAQ:HOLX - Get Free Report）于 7 月 29 日星期一公布了其季度收益结果。这家医疗设备提供商报告称，该季度每股收益为 1.06 美元，超过了 1.02 美元的共识预期 0.04 美元。该季度公司收入为 101 亿美元，而分析师预计为 100 亿美元。Hologic 的净利润率为 17.59%，净资产回报率为 19.53%。公司季度收入同比增长了 2.7%。在去年同期的同一季度，该公司每股收益为 0.93 美元。股票研究分析师预计，Hologic, Inc.本财年的每股收益将达到 4.08 美元。</p>
<h2>Hologic 内部交易活动</h2>
<p>在其他 Hologic 新闻中，首席执行官 Stephen P. Macmillan 于 7 月 17 日星期三交易中出售了 3,672 股 Hologic 股票。这些股票的平均价格为 80.13 美元，总交易额为 294,237.36 美元。交易完成后，首席执行官现在拥有公司股票 1,157,562 股，价值约 92,755,443.06 美元。该交易已在提交给证券交易委员会的文件中披露，可在此链接找到。另外，首席执行官 Stephen P. Macmillan 于 7 月 17 日星期三的交易中出售了公司股票 3,672 股。股票的平均价格为 80.13 美元，总价值为 294,237.36 美元。交易完成后，首席执行官现在直接持有公司股票 1,157,562 股，价值约 92,755,443.06 美元。该交易已在证券交易委员会的法律文件中披露，可通过 SEC 网站访问。此外，内部人员 Brandon Schnittker 于 8 月 6 日星期二的交易中出售了 476 股 Hologic 股票。这些股票的平均价格为 83.11 美元，总价值为 39,560.36 美元。交易完成后，该内部人员现在持有公司股票 3,735 股，价值 310,415.85 美元。过去三个月，内部人员已出售了价值 1,469,973 美元的 18,280 股公司股票。公司内部人员持有公司股份的比例为 1.75%。</p>
<h2>分析师评级变动</h2>
<p>一些研究公司最近发布了关于 HOLX 的报告。加拿大皇家银行重申了对 Hologic 的 “行业表现” 评级，并设定了 82.00 美元的股价目标。Needham \u0026 Company LLC 重申了对 Hologic 的 “买入” 评级，并设定了 90.00 美元的目标股价。StockNews.com 将 Hologic 的股票评级从 “强买” 调降至 “买入”，并在 8 月 10 日的报告中指出。Stephens 重申了对 Hologic 的 “增持” 评级，并设定了 92.00 美元的股价目标。最后，Argus 将 Hologic 的目标股价从 89.00 美元上调至 95.00 美元，并给予该公司 “买入” 评级。四家研究分析公司对该股票给予持有评级，八家给予买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “中度买入”，平均目标股价为 87.60 美元。</p>
<p><strong>获取我们对 HOLX 的最新股票分析</strong></p>
<h2>Hologic 简介（免费报告）</h2>
<p>Hologic, Inc（豪洛捷公司）开发、制造和供应诊断产品、医学影像系统和妇女健康手术产品，通过早期检测和治疗服务于妇女健康。该公司通过四个部门运营：诊断、乳腺健康、妇科手术和骨骼健康。它提供 Aptima 分子诊断试剂以检测感染微生物；Aptima 病毒载量试剂用于乙型肝炎病毒、丙型肝炎病毒、人类免疫缺陷病毒和人类巨细胞病毒；Aptima 细菌性阴道病和念珠菌性阴道炎试剂用于阴道炎的诊断；Aptima 新型冠状病毒（SARS-CoV-2）和 Panther Fusion 新型冠状病毒试剂用于检测新型冠状病毒；ThinPrep 系统用于细胞学应用；以及 Rapid Fetal Fibronectin Test 用于帮助医生评估早产风险。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们比 Hologic 更喜欢的股票</li>
<li>投资高市盈率成长股</li>
<li>CAVA 股票上涨，盈利证实它是一家顶级成长股</li>
<li>股票情绪分析：工作原理</li>
<li>MarketBeat 周评 - 8/19 - 8/23</li>
<li>如何计算期权利润</li>
<li>3 只高空头头寸股票准备进行利率削减挤压</li>
</ul>
<p><strong>想看看其他对 HOLX 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Hologic, Inc.（纳斯达克股票代码：HOLX - 免费报告）的最新 13F 申报和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9MWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9MWA"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 你被欺骗了 615 天，而且还在继续（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTEy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTEy"/></p>
<h2>现在是否值得投资 1,000 美元购买 Hologic 股票？</h2>
<p>在考虑 Hologic 之前，您会想听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票... 而 Hologic 不在名单上。</p>
<p>虽然 Hologic 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

豪洛捷

<p>Cypress Capital Group 在第二季度将其在 Hologic, Inc. (NASDAQ: HOLX) 的持股比例减少了 75.9%，出售了 9,607 股后，持有 3,050 股。该公司最新的申报显示，其 Hologic 股票价值为$1,000。其他投资者也增持或建立了 Hologic 的持股，包括各种对冲基金。截至目前，公司股份的 94.73% 归机构持有。Hologic 最近公布了季度收益，并经历了首席执行官 Stephen P. Macmillan 等内部人士的减持。分析师们为该股设定了各种价格目标</p>

<p>Cypress Capital Group lowered its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 75.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,050 shares of the medical equipment provider's stock after selling 9,607 shares during the period. Cypress Capital Group's holdings in Hologic were worth $226,000 as of its most recent SEC filing.</p>
<ul>
<li>Time to buy these 3 healthcare companies that raised revenue guidance?</li>
</ul>
<div class="lb-trans"><p>Cypress Capital Group 在第二季度减持了 Hologic, Inc.（NASDAQ:HOLX - Free Report）的持股，根据该公司最近向证券交易委员会（SEC）提交的文件，持股比例下降了 75.9%。该公司在此期间卖出了 9,607 股，持有这家医疗设备提供商的 3,050 股股票。截至最近一次提交的 SEC 文件，Cypress Capital Group 持有的 Hologic 股份价值 226,000 美元。</p>
<ul>
<li>是时候购买这 3 家提高收入预测的医疗公司了吗？</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently bought and sold shares of the business. iA Global Asset Management Inc. acquired a new position in Hologic in the 1st quarter valued at about $37,000. Mather Group LLC. purchased a new stake in Hologic in the 1st quarter valued at approximately $48,000. Massmutual Trust Co. FSB ADV raised its position in Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider's stock worth $54,000 after acquiring an additional 137 shares in the last quarter. Toth Financial Advisory Corp increased its holdings in shares of Hologic by 81.1% in the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider's stock valued at $60,000 after purchasing an additional 347 shares in the last quarter. Finally, Fidelis Capital Partners LLC purchased a new stake in Hologic during the first quarter worth about $63,000. 94.73% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也买入和卖出了该公司的股票。iA Global Asset Management Inc.在第一季度新建了 Hologic 的头寸，价值约 37,000 美元。Mather Group LLC.在第一季度购入了一份价值约 48,000 美元的 Hologic 股票。Massmutual Trust Co. FSB ADV 在第一季度将其在 Hologic 的持仓增加了 24.7%。Massmutual Trust Co. FSB ADV 现在拥有 691 股这家医疗设备提供商的股票，价值 54,000 美元，比上一季度增加了 137 股。Toth Financial Advisory Corp 在第一季度将其在 Hologic 的持股增加了 81.1%。Toth Financial Advisory Corp 现在拥有 775 股这家医疗设备提供商的股票，价值 60,000 美元，比上一季度增加了 347 股。最后，Fidelis Capital Partners LLC 在第一季度购入了一份价值约 63,000 美元的 Hologic 股票。94.73% 的股份由对冲基金和其他机构投资者持有。</p>
</div><h2>Hologic Price Performance</h2>
<div class="lb-trans"><h2>Hologic 股价表现</h2>
</div><p>Shares of NASDAQ HOLX traded up $0.16 during mid-day trading on Friday, reaching $80.25. 1,106,135 shares of the company traded hands, compared to its average volume of 1,648,404. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $84.67. The firm has a market cap of $18.73 billion, a PE ratio of 40.94, a price-to-earnings-growth ratio of 2.64 and a beta of 0.99. The stock has a fifty day simple moving average of $77.75 and a 200-day simple moving average of $76.14. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.29.</p>
<ul>
<li>Can Butterfly Network Spread its Wings in 2023?</li>
</ul>
<div class="lb-trans"><p>NASDAQ HOLX 股票在周五的午间交易中上涨了 0.16 美元，达到 80.25 美元。公司股票交易量为 1,106,135 股，相比其平均交易量 1,648,404 股有所下降。Hologic, Inc.的 52 周最低价为 64.02 美元，52 周最高价为 84.67 美元。该公司的市值为 187.3 亿美元，市盈率为 40.94，市盈增长比为 2.64，贝塔系数为 0.99。股票的 50 天简单移动平均线为 77.75 美元，200 天简单移动平均线为 76.14 美元。公司的资产负债比为 0.51，流动比率为 3.99，速动比率为 3.29。</p>
<ul>
<li>蝴蝶网络能否在 2023 年扩展业务？</li>
</ul>
</div><p>Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm's quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.93 earnings per share. Equities research analysts anticipate that Hologic, Inc. will post 4.08 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Hologic（NASDAQ:HOLX - Get Free Report）于 7 月 29 日星期一公布了其季度收益结果。这家医疗设备提供商报告称，该季度每股收益为 1.06 美元，超过了 1.02 美元的共识预期 0.04 美元。该季度公司收入为 101 亿美元，而分析师预计为 100 亿美元。Hologic 的净利润率为 17.59%，净资产回报率为 19.53%。公司季度收入同比增长了 2.7%。在去年同期的同一季度，该公司每股收益为 0.93 美元。股票研究分析师预计，Hologic, Inc.本财年的每股收益将达到 4.08 美元。</p>
</div><h2>Insider Activity at Hologic</h2>
<div class="lb-trans"><h2>Hologic 内部交易活动</h2>
</div><p>In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company's stock, valued at approximately $92,755,443.06. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the company's stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the transaction, the chief executive officer now directly owns 1,157,562 shares of the company's stock, valued at approximately $92,755,443.06. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now owns 3,735 shares of the company's stock, valued at $310,415.85. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,280 shares of company stock valued at $1,469,973. Corporate insiders own 1.75% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Hologic 新闻中，首席执行官 Stephen P. Macmillan 于 7 月 17 日星期三交易中出售了 3,672 股 Hologic 股票。这些股票的平均价格为 80.13 美元，总交易额为 294,237.36 美元。交易完成后，首席执行官现在拥有公司股票 1,157,562 股，价值约 92,755,443.06 美元。该交易已在提交给证券交易委员会的文件中披露，可在此链接找到。另外，首席执行官 Stephen P. Macmillan 于 7 月 17 日星期三的交易中出售了公司股票 3,672 股。股票的平均价格为 80.13 美元，总价值为 294,237.36 美元。交易完成后，首席执行官现在直接持有公司股票 1,157,562 股，价值约 92,755,443.06 美元。该交易已在证券交易委员会的法律文件中披露，可通过 SEC 网站访问。此外，内部人员 Brandon Schnittker 于 8 月 6 日星期二的交易中出售了 476 股 Hologic 股票。这些股票的平均价格为 83.11 美元，总价值为 39,560.36 美元。交易完成后，该内部人员现在持有公司股票 3,735 股，价值 310,415.85 美元。过去三个月，内部人员已出售了价值 1,469,973 美元的 18,280 股公司股票。公司内部人员持有公司股份的比例为 1.75%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research firms have recently issued reports on HOLX. Royal Bank of Canada reiterated a &#34;sector perform&#34; rating and set a $82.00 price target on shares of Hologic in a research report on Friday, August 16th. Needham &amp; Company LLC restated a &#34;buy&#34; rating and set a $90.00 target price on shares of Hologic in a report on Tuesday, July 30th. StockNews.com downgraded shares of Hologic from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, August 10th. Stephens restated an &#34;overweight&#34; rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Finally, Argus upped their target price on Hologic from $89.00 to $95.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, May 9th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $87.60.</p>
<div class="lb-trans"><p>一些研究公司最近发布了关于 HOLX 的报告。加拿大皇家银行重申了对 Hologic 的 “行业表现” 评级，并设定了 82.00 美元的股价目标。Needham \u0026 Company LLC 重申了对 Hologic 的 “买入” 评级，并设定了 90.00 美元的目标股价。StockNews.com 将 Hologic 的股票评级从 “强买” 调降至 “买入”，并在 8 月 10 日的报告中指出。Stephens 重申了对 Hologic 的 “增持” 评级，并设定了 92.00 美元的股价目标。最后，Argus 将 Hologic 的目标股价从 89.00 美元上调至 95.00 美元，并给予该公司 “买入” 评级。四家研究分析公司对该股票给予持有评级，八家给予买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “中度买入”，平均目标股价为 87.60 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on HOLX</strong></p>
<div class="lb-trans"><p><strong>获取我们对 HOLX 的最新股票分析</strong></p>
</div><h2>Hologic Profile (Free Report)</h2>
<div class="lb-trans"><h2>Hologic 简介（免费报告）</h2>
</div><p>Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.</p>
<div class="lb-trans"><p>Hologic, Inc（豪洛捷公司）开发、制造和供应诊断产品、医学影像系统和妇女健康手术产品，通过早期检测和治疗服务于妇女健康。该公司通过四个部门运营：诊断、乳腺健康、妇科手术和骨骼健康。它提供 Aptima 分子诊断试剂以检测感染微生物；Aptima 病毒载量试剂用于乙型肝炎病毒、丙型肝炎病毒、人类免疫缺陷病毒和人类巨细胞病毒；Aptima 细菌性阴道病和念珠菌性阴道炎试剂用于阴道炎的诊断；Aptima 新型冠状病毒（SARS-CoV-2）和 Panther Fusion 新型冠状病毒试剂用于检测新型冠状病毒；ThinPrep 系统用于细胞学应用；以及 Rapid Fetal Fibronectin Test 用于帮助医生评估早产风险。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Hologic</li>
<li>Investing in the High PE Growth Stocks</li>
<li>CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>MarketBeat Week in Review – 8/19 - 8/23</li>
<li>How to Calculate Options Profits</li>
<li>3 High Short-Interest Stocks Poised for a Rate Cut Squeeze</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>五只我们比 Hologic 更喜欢的股票</li>
<li>投资高市盈率成长股</li>
<li>CAVA 股票上涨，盈利证实它是一家顶级成长股</li>
<li>股票情绪分析：工作原理</li>
<li>MarketBeat 周评 - 8/19 - 8/23</li>
<li>如何计算期权利润</li>
<li>3 只高空头头寸股票准备进行利率削减挤压</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding HOLX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 HOLX 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Hologic, Inc.（纳斯达克股票代码：HOLX - 免费报告）的最新 13F 申报和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9MWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=HOLX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ You’ve been lied to for 615 days, and counting (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 你被欺骗了 615 天，而且还在继续（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTEy" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9112&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Hologic right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1,000 美元购买 Hologic 股票？</h2>
</div><p>Before you consider Hologic, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Hologic 之前，您会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票... 而 Hologic 不在名单上。</p>
</div><p>While Hologic currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hologic 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

豪洛捷公司（NASDAQ:HOLX）的股票被 Cypress Capital Group 出售